Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Hypertension. 2020 Aug 12;76(3):651–661. doi: 10.1161/HYPERTENSIONAHA.120.15595

Figure 3: ADAM17-mediated cleavage of monomeric ACE2 and release of soluble sACE2 ectodomain.

Figure 3:

Left panel shows membrane-bound ACE2 (pdb: 6m17, gold) with box-outlined putative ADAM17 cleavage target site, red. The middle panel depicts ADAM17 (pdb:2m2f+2fv9) docking at its cleavage site within membrane-bound ACE2. The Zn2+ cofactor of ADAM17 is shown as a magenta sphere. The right panel shows the release of soluble sACE2 ectodomain following ADAM1 cleavage, leaving the membrane-bound C-terminal collectrin-like domain of ACE2. sACE ectodomain possess the enzymatic activity and the SARS-CoV-2 spike binding site.